PharmOptima Scientists Present Study Posters at the June 2012 Spinal Muscular Atrophy Foundation Seminar
PORTAGE, MICHIGAN, June 26, 2012 – PharmOptima LLC announced that three of its scientists authored a study paper at the Spinal Muscular Atrophy Foundation Seminar held in Minneapolis last week. The abstracts entitled “Development of SMA mouse model plasma protein biomarker assays” and “Optimization of peripheral blood mononuclear cell processing fro SMN protein signal analysis” were co-authored by Dr. Roger Poorman, Mr. Douglas Decker and Mr. Phillip Zaworski, all scientists at PharmOptima in Portage, Michigan along with others representing the Spinal Muscular Atrophy Foundation.
Spinal Muscular Atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Patients afflicted by SMA lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe, depending on the severity of the disease. It is estimated that approximately 1 in 6,000 -10,000 infants are born with SMA.
Mr. Douglas Decker, Vice President at PharmOptima, said “… the studies identified factors that affect SMN levels in blood peripheral blood mononuclear cells. A quantitative understanding of these factors is critical in order to properly correlate SMN levels to disease progression.” The posters can be viewed in detail at the PharmOptima website www.pharmoptima.com.
Mr. Douglas Decker, Vice President